Bullish Case: IMAX holds realized momentum (+20.7% in 90d, +63% YoY) with Odyssey now the highest-grossing IMAX release ever, Q2 revenue +12% and adjusted EPS +65%, and a loaded slate: Godzilla Minus Zero (Nov 6), Everest doc (Oct 30), Dune: Part Three, and 2027 Star Wars 70mm tie-ins. Calls traded 99% over puts, B. Riley and Rosenblatt targets ($60-61) sit ~13% above spot, and the Helium density places mass at $50-55 with an upper node at $55.

Bearish Case: At $53.45 near the record $55.57 high, valuation is stretched (214% five-year gain) and good news is priced; CNBC notes sale interest has no bidders, removing a catalyst. Term structure is backwardated with 62-63% near-dated IV and put skew (Dec 55P at 55% vol) signaling event risk. Macro spillover from an SPY drawdown, faded Odyssey demand, or brand-dilution criticism could compress shares toward the $48-50 node where Helium's density also concentrates.

Potential Outcomes:

1. Consolidation $50-56 (40%): drift with Oct 30 Everest and Godzilla trailers; falsified by breaks below $50.
2. Rally to $58-62 (25%): Godzilla Minus Zero (Nov
   
   6) and Dune 3 buzz drive record Q3 print; watch Nov earnings and 70mm extension odds (Polymarket 61-74%).
3. Pullback to $46-50 (22%): post-Odyssey demand fade, 'no one buying' sale narrative confirmed dead.
4. Macro shock < $44 (8%): SPY dislocation; backwardated IV and put skew already price this tail.
5. M&A headline either way (5%): buyer emerges or explicit 'not for sale' statement.

September 15, 2026